Author's response to reviews

Title: Complete Pathologic Response of HER2-Positive Breast Cancer Liver Metastasis with Dual Anti-HER2 Antagonism

Authors:
- Hans F Schoellhammer (hschoellhammer@coh.org)
- Felicia Hsu (feliciah@mit.edu)
- Courtney Vito (cvito@coh.org)
- Peiguo Chu (pchu@coh.org)
- Jinha Park (jinpark@coh.org)
- James Waisman (jwaisman@coh.org)
- Joseph Kim (jokim@coh.org)

Version: 2
Date: 7 February 2014

Author's response to reviews: see over
Dear Sir/Madam,

We thank the reviewers for their comments regarding our case report manuscript written by Hans F. Schoellhammer and colleagues from City of Hope Comprehensive Cancer Center in Duarte, California, USA, entitled “Complete Pathologic Response of HER2-Positive Breast Cancer Liver Metastasis with Dual Anti-HER2 Antagonism,” which we had submitted for consideration for publication in *BMC Cancer*. We wish to address the reviewers’ points regarding our manuscript as well as the discretionary revisions and changes that we have made in accordance with their comments, which we list in bold below.

1. **Case presentation- paragraph 1**: No detail is given regarding the patients comorbidities or demographic data. Please add some of this detail.

Details regarding the patient’s demographics and co-morbidities have been added to Paragraph 1.

2. **Case presentation- paragraph 3**: The dose and schedule of pertuzumab is described in detail, however the schedules for docetaxel and pertuzumab are not provided. Please provide these schedules.

Details regarding the schedules and dosing of docetaxel, trastuzumab, and pertuzumab have been added to Paragraph 3.

3. **Case presentation- paragraph 3**: Please detail the dose and schedule of radiation the patient received.

The patient’s post-mastectomy radiation was performed at an outside radiation oncology facility and we are not able to obtain exact details regarding the dose and schedule.

4. **Case presentation- The overall timeline of the patient’s course of care is unclear. From the time of diagnosis to resection of primary, to resection of BCLM. Please clarify the temporal course of the patient's care.**

The temporal course of the patient’s care has been clarified and the intervals of time between resections have been added to the manuscript.
5. Case presentation- The authors cite literature validated rationale for all clinical decisions taken in the course of the patients care except one. Why was the patient continued on Trastuzumab/Pertuzumab for a year following successful resection of BCLM?

The optimal duration of anti-HER2 therapy in the metastatic setting for patients that appear to have long-term disease control is not known, and there are no formal guidelines as of yet for this duration. The manuscript has been changed to reflect the fact that the patient will be continued on dual anti-HER2 therapy indefinitely at this time, and an additional reference has been added.

Once again, we thank the reviewers for their comments and we have made the recommended discretionary revisions. We respectfully return our revised manuscript for consideration for publication in *BMC Cancer*.

Sincerely,
Joseph Kim, MD
Associate Professor of Surgery
Division of Surgical Oncology
City of Hope Comprehensive Cancer Center
Duarte, CA USA